Biocon’s Differentiated Innovation Story Beginning to Pay Off

Biocon’s biopharma journey took off on a differentiated path fraught with challenges.  In the late 90’s when we started the prevailing business ethos in pharmaceutical sector favored a predictable and attractive ROCE (Return On Capital Employed) ventures based on chemically synthesized generic drugs. Biocon, however, chose to invest in developing biologic drugs based on recombinant…

We expect the momentum in the Biologics business to continue, says Biocon CFO

Biocon reported better-than-expected revenue and profit in the second quarter of FY19 on the back of good performance by its Biologics, Research Services and Small Molecules business segments. Siddharth Mittal, President (Finance) and CFO, spoke to by K Giriprakash and Venkatesh Ganesh of Hindu BusinessLine about the company’s results and prospects. Excerpts from the interview….

Wonder Women of Biocon

On International Women’s Day, Biocon salutes the indomitable spirit of it’s Wonder Women!